scispace - formally typeset
C

C. Frank Bennett

Researcher at Isis Pharmaceuticals

Publications -  323
Citations -  37204

C. Frank Bennett is an academic researcher from Isis Pharmaceuticals. The author has contributed to research in topics: Oligonucleotide & RNA. The author has an hindex of 85, co-authored 313 publications receiving 31945 citations. Previous affiliations of C. Frank Bennett include Harvard University & University of Utah.

Papers
More filters
Journal ArticleDOI

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.

TL;DR: IMR-122 inhibition in a diet-induced obesity mouse model resulted in decreased plasma cholesterol levels and a significant improvement in liver steatosis, accompanied by reductions in several lipogenic genes, suggesting that miR- 122 may be an attractive therapeutic target for metabolic disease.
Journal ArticleDOI

The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation.

TL;DR: Evidence is provided for a role for the long nuclear-retained regulatory RNA, MALAT1 in AS regulation and for the role for an nrRNA in the regulation of gene expression, which suggests that MALat1 regulates AS by modulating the levels of active SR proteins.
Journal ArticleDOI

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

Richard S. Finkel, +397 more
TL;DR: Those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group and infants with a shorter disease duration at screening wereMore likely than those with a longer disease duration to benefit from nusineren.
Journal ArticleDOI

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

TL;DR: The molecular mechanisms by which antisense oligonucleotides can be designed to modulate RNA function in mammalian cells and how synthetic oligon nucleotides behave in the body are focused on.